Hypobaria and Traumatic Pneumothorax
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01670942|
Recruitment Status : Completed
First Posted : August 23, 2012
Last Update Posted : April 28, 2014
The purpose of this research is to see if people who have had a collapsed lung that has been re-expanded can be safely taken to an elevation that a person might experience while in a commercial airplane without having their lung partially collapse again, or have any symptoms such as feeling short of breath or having oxygen levels in the blood decrease while at the simulated altitude.
The investigators hypothesize that subjects who have had a collapsed lung that has been re-expanded will not have any adverse symptoms or signs while subjected to a simulated altitude of 8400 feet (565mm Hg) or 12650 ft (471mm Hg).
|Condition or disease||Intervention/treatment|
|Pneumothorax||Other: hypobaric chamber|
|Study Type :||Observational|
|Actual Enrollment :||20 participants|
|Official Title:||The Effects of Hypobaric Conditions on Small, Traumatic Pneumothoraces|
|Study Start Date :||October 2012|
|Actual Primary Completion Date :||December 2013|
|Actual Study Completion Date :||December 2013|
Other: hypobaric chamber
We will use a large (26 tons) multi-place hyperbaric and hypobaric chamber at IMC in Murray, Utah (elevation 1500m or 4500ft, average ambient barometric pressure 645mm Hg). In the hypobaric study, the barometric pressure will be lowered to 554mm Hg (phase 1) or 471mm Hg (phase 2) over 20 minutes and held there for two hours.
- Change in pneumothorax size [ Time Frame: baseline and 2 hours ]Will document pneumothorax size before simulated altitude, and size after being at simulated altitude for two hours
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01670942
|United States, Utah|
|Intermountain Medical Center|
|Murray, Utah, United States, 84157|
|Principal Investigator:||Sarah Majercik, MD, MBA||Intermountain Health Care, Inc.|
|Study Director:||Lindell Weaver, MD||Intermountain Health Care, Inc.|